Keros Therapeutics (KROS) Total Liabilities (2019 - 2026)
Keros Therapeutics' (KROS) quarterly Total Liabilities came in at $34.9 million in Q4 2025, down 21.3% YoY from $44.3 million in Q4 2024, and down 11.0% on a QoQ basis from $39.2 million in Q3 2025.
Keros Therapeutics (KROS) Total Liabilities (2019 - 2026) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of Total Liabilities data on file, last reported at $34.9 million in Q4 2025.
- Quarterly Total Liabilities fell 21.3% year-over-year to $34.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $34.9 million (down 21.3% YoY) and the FY2025 annual result came in at $34.9 million, down 21.3% from the prior year.
- Total Liabilities retreated to $34.9 million in Q4 2025, from $39.2 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $55.7 million in Q1 2025 to a low of $7.8 million in Q2 2021.
- A 5-year average of $28.7 million and a median of $30.2 million in 2023 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2023 — Total Liabilities soared 163.82% — and 2025, when it declined 21.3%.
- Tracing KROS's Total Liabilities over 5 years: stood at $12.1 million in 2021, then surged by 143.09% to $29.4 million in 2022, then gained by 28.8% to $37.8 million in 2023, then increased by 17.25% to $44.3 million in 2024, then decreased by 21.3% to $34.9 million in 2025.
- The last three Total Liabilities figures came in at $34.9 million (Q4 2025), $39.2 million (Q3 2025), and $50.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.59 Bn | 131.73 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.21 Bn | 78.22 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.65 Bn | 60.47 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 10.03 Bn |
| 10 | Keros Therapeutics | 215.92 Mn | -41.68 Mn | - | 25.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.28 Mn |
| Dec 31, 2025 | 34.89 Mn |
| Sep 30, 2025 | 39.20 Mn |
| Jun 30, 2025 | 50.43 Mn |
| Mar 31, 2025 | 55.69 Mn |
| Dec 31, 2024 | 44.33 Mn |
| Sep 30, 2024 | 46.44 Mn |
| Jun 30, 2024 | 34.11 Mn |
| Mar 31, 2024 | 31.87 Mn |
| Dec 31, 2023 | 37.81 Mn |
| Sep 30, 2023 | 30.41 Mn |
| Jun 30, 2023 | 30.05 Mn |
| Mar 31, 2023 | 29.45 Mn |
| Dec 31, 2022 | 29.36 Mn |
| Sep 30, 2022 | 11.53 Mn |
| Jun 30, 2022 | 15.45 Mn |
| Mar 31, 2022 | 11.65 Mn |
| Dec 31, 2021 | 12.08 Mn |
| Sep 30, 2021 | 11.48 Mn |
| Jun 30, 2021 | 7.81 Mn |